CIK 0000818686 · Large accelerated filer
TEVA PHARMACEUTICAL INDUSTRIES LTD
Sign in to watch- Ticker
- TEVA
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Israel
- Entity type
- operating
- Phone
- 972 (3) 914-8213
- Business address
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED, 124 DVORA HANEVI'A ST., TEL AVIV, Israel
- Former names
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $33,242,786
- in 10 filings, $10.6M under 10b5-1 plans
Net −$33,242,786. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-02-28 | Drape Eric Executive VP Global Operations | Option exercise · Restricted Share Units | −19,514 | 19,515 | ||
| 2023-02-28 | Drape Eric Executive VP Global Operations | Option exercise · Restricted Share Units | −47,598 | 0 | ||
| 2023-02-28 | Dethlefs Sven EVP, North America Commercial | Option exercise | +17,346 | 182,727 | ||
| 2023-02-28 | Dethlefs Sven EVP, North America Commercial | Sale | −17,346 | $9.89 | $171K | 165,381 |
| 2023-02-28 | Dethlefs Sven EVP, North America Commercial | Option exercise | +42,309 | 207,690 | ||
| 2023-02-28 | Dethlefs Sven EVP, North America Commercial | Sale | −42,309 | $9.89 | $418K | 165,381 |
| 2023-02-28 | Dethlefs Sven EVP, North America Commercial | Option exercise · Restricted Share Units | −17,346 | 17,346 | ||
| 2023-02-28 | Dethlefs Sven EVP, North America Commercial | Option exercise · Restricted Share Units | −42,309 | 0 | ||
| 2023-02-28 | Daniell Richard Exec. VP, European Commercial | Option exercise | +20,598 | 63,780 | ||
| 2023-02-28 | Daniell Richard Exec. VP, European Commercial | Sale | −20,598 | $9.89 | $204K | 43,182 |
| 2023-02-28 | Daniell Richard Exec. VP, European Commercial | Option exercise | +50,242 | 93,424 | ||
| 2023-02-28 | Daniell Richard Exec. VP, European Commercial | Sale | −23,654 | $9.89 | $234K | 69,770 |
| 2023-02-28 | Daniell Richard Exec. VP, European Commercial | Option exercise · Restricted Share Units | −20,598 | 20,599 | ||
| 2023-02-28 | Daniell Richard Exec. VP, European Commercial | Option exercise · Restricted Share Units | −50,242 | 0 | ||
| 2023-02-15 | Francis Richard D President and CEO | Grant or award · Restricted Share Units | +484,966 | 484,966 | ||
| 2023-02-13 | Kalif Eliyahu Sharon EVP, Chief Financial Officer | Option exercise | +6,629 | 16,005 | ||
| 2023-02-13 | Kalif Eliyahu Sharon EVP, Chief Financial Officer | Option exercise · Restricted Share Units | −6,629 | 6,630 | ||
| 2023-02-07 | Stark David Matthew Exec. VP Chief Legal Officer | Grant or award · Restricted Share Units | +44,953 | 44,953 | ||
| 2023-02-07 | Sabag Mark EVP, International Markets | Grant or award · Restricted Share Units | +50,242 | 50,242 | ||
| 2023-02-07 | Kalif Eliyahu Sharon EVP, Chief Financial Officer | Grant or award · Restricted Share Units | +44,953 | 44,953 |
Page 33 of 76 · 1,517 trades